Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company. The Company offers oral formulation of an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Website: siga.com



Growth: Good revenue growth rate 88.9%, there is acceleration compared to average historical growth rates 70.1%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is positive, +62.2%. On average the margin is improving steadily. Gross margin is high, +53.7%.

Cash Flow Generation: Dividend yield for the last twelve months 10.1%. Free cash flow yield 17.4% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 37.8% higher than minimum and 77.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 8.4x by EV / Sales multiple , the company can be >100% undervalued

Key Financials (Download financials)

Ticker: SIGA
Share price, USD:  (+0.6%)5.955
year average price 7.24  


year start price 8.81 2024-04-13

max close price 11.97 2024-08-14

min close price 5.22 2025-04-03

current price 5.96 2025-04-12
Common stocks: 72 929 550

Dividend Yield:  10.1%
FCF Yield LTM: 17.4%
EV / LTM EBITDA: 3.5x
EV / EBITDA annualized: 26.5x
EV / Sales: 2.1x
Margin (EBITDA LTM / Revenue): 62.2%
Fundamental value created in LTM:
Market Cap ($m): 432
Net Debt ($m): -114
EV (Enterprise Value): 318
Price to Book: 2.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-04-08globenewswire.com

SIGA Declares Special Cash Dividend of $0.60 Per Share

2025-04-07zacks.com

Siga Technologies Inc. (SIGA) Declines More Than Market: Some Information for Investors

2025-04-07seekingalpha.com

SIGA Technologies: Asymmetric Upside, If 2025 Goes Right

2025-03-17zacks.com

Siga Technologies Inc. (SIGA) Rises Higher Than Market: Key Facts

2025-03-11seekingalpha.com

SIGA Technologies, Inc. (SIGA) Q4 2024 Earnings Call Transcript

2025-03-04zacks.com

Siga Technologies Inc. (SIGA) Ascends While Market Falls: Some Facts to Note

2025-02-11zacks.com

Siga Technologies Inc. (SIGA) Stock Drops Despite Market Gains: Important Facts to Note

2025-01-23zacks.com

Siga Technologies Inc. (SIGA) Surpasses Market Returns: Some Facts Worth Knowing

2025-01-15zacks.com

Siga Technologies Inc. (SIGA) Advances But Underperforms Market: Key Facts

2025-01-02globenewswire.com

TEPOXX (tecovirimat) Approved in Japan for the Treatment of Orthopoxviruses
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SIGA SIGA SIGA SIGA SIGA SIGA SIGA SIGA SIGA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-01 2024-05-07 2024-03-12 2023-11-07 2023-08-08 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-11-07 16:55:58 2024-08-01 16:59:05 2024-05-07 16:58:12 2024-03-12 17:00:41 2023-11-07 17:00:18 2023-08-08 16:50:42 2023-05-04 16:52:58 2023-03-02 16:55:27 2022-11-03 17:06:16
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 10M 22M 25M 116M 9M 6M 8M 11M 72M
costOfRevenue 2M 12M 3M 15M 5M 6M 6M 7M 10M
grossProfit 8M 9M 22M 102M 5M -212 408 2M 4M 63M
grossProfitRatio 0.838 0.436 0.873 0.873 0.508 -0.036 0.256 0.358 0.866
researchAndDevelopmentExpenses 1M 3M 3M 3M 1M 5M 3M 16M 7M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 6M 8M 7M 6M 4M 4M 6M 20M
otherExpenses 2M 1M 2M 1M 883 148 1M -3M -16M -7M
operatingExpenses 8M 8M 11M 10M 6M 4M 4M 6M 20M
costAndExpenses 9M 21M 14M 25M 11M 11M 10M 13M 29M
interestIncome 0 0 0 1M 883 148 1M 0 0 0
interestExpense 0 0 0 890 629 0 0 -890 629 755 333 -258 975
depreciationAndAmortization 0 140 839 138 471 43 812 135 924 133 657 131 121 2M 130 203
ebitda 542 087 1M 11M 92M -1M -5M -2M -240 927 43M
ebitdaratio 0.054 0.056 0.449 0.788 -0.127 -0.789 -0.238 -0.021 0.596
operatingIncome 542 087 1M 11M 92M -1M -5M -2M -2M 43M
operatingIncomeRatio 0.054 0.05 0.443 0.787 -0.142 -0.789 -0.253 -0.159 0.594
totalOtherIncomeExpensesNet 1M 1M 2M 1M 883 148 1M 890 629 677 233 258 975
incomeBeforeTax 2M 2M 13M 93M -426 096 -3M -1M -1M 43M
incomeBeforeTaxRatio 0.187 0.11 0.52 0.797 -0.046 -0.587 -0.146 -0.099 0.597
incomeTaxExpense 528 647 565 219 3M 21M -33 030 -572 186 -299 422 -315 669 10M
netIncome 1M 2M 10M 72M -393 066 -3M -918 255 -811 794 33M
netIncomeRatio 0.134 0.084 0.404 0.62 -0.043 -0.489 -0.11 -0.071 0.458
eps 0.019 0.026 0.14 1.02 -0.006 -0.04 -0.013 -0.011 0.45
epsdiluted 0.019 0.026 0.14 1.02 -0.006 -0.04 -0.013 -0.011 0.45
weightedAverageShsOut 71M 71M 71M 71M 71M 71M 72M 73M 73M
weightedAverageShsOutDil 72M 72M 72M 71M 71M 71M 72M 74M 73M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SIGA SIGA SIGA SIGA SIGA SIGA SIGA SIGA SIGA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-01 2024-05-07 2024-03-12 2023-11-07 2023-08-08 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-11-07 16:55:58 2024-08-01 16:59:05 2024-05-07 16:58:12 2024-03-12 17:00:41 2023-11-07 17:00:18 2023-08-08 16:50:42 2023-05-04 16:52:58 2023-03-02 16:55:27 2022-11-03 17:06:16
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 99M 107M 144M 150M 71M 76M 116M 99M 110M
shortTermInvestments 0 0 0 0 0 0 0 0 0
cashAndShortTermInvestments 99M 107M 144M 150M 71M 76M 116M 99M 110M
netReceivables 12M 9M 18M 21M 8M 6M 12M 45M 55M
inventory 62M 56M 64M 64M 65M 50M 43M 39M 31M
otherCurrentAssets 7M 5M 2M 3M 2M 2M 2M 2M 964 065
totalCurrentAssets 181M 176M 228M 239M 146M 134M 173M 186M 197M
propertyPlantEquipmentNet 1M 2M 1M 1M 1M 2M 2M 2M 2M
goodwill 898 334 898 334 898 334 898 334 898 334 898 334 898 334 898 334 898 334
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 898 334 898 334 898 334 898 334 898 334 898 334 898 334 898 334 898 334
longTermInvestments 0 0 0 0 0 0 0 0 0
taxAssets 12M 12M 11M 12M 8M 8M 7M 6M 4M
otherNonCurrentAssets 253 605 2M 2M 2M 2M 2M 2M 252 546 261 814
totalNonCurrentAssets 15M 16M 15M 16M 12M 12M 11M 9M 7M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 195M 193M 243M 255M 158M 147M 184M 195M 204M
accountPayables 1M 1M 3M 1M 564 272 1M 1M 3M 2M
shortTermDebt 535 234 523 889 503 470 564 009 554 732 545 558 536 627 528 170 519 198
taxPayables 127 815 82 457 3M 22M 54 432 11 822 1M 1M 9M
deferredRevenue 14M 14M 21M 21M 22M 11M 11M 11M 10M
otherCurrentLiabilities 7M 6M 51M 31M 8M 6M 6M 7M 14M
totalCurrentLiabilities 22M 21M 75M 54M 31M 19M 18M 22M 27M
longTermDebt 0 0 837 083 335 991 0 0 0 0 0
deferredRevenueNonCurrent 0 0 0 -335 991 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 483 338 0 0 0 0 0
otherNonCurrentLiabilities 4M 4M 3M 3M 3M 3M 3M 3M -9M
totalNonCurrentLiabilities 4M 4M 3M 4M 3M 3M 3M 3M 4M
otherLiabilities 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 535 234 523 889 800 000 900 000 554 732 545 558 536 627 528 170 519 198
totalLiabilities 26M 25M 78M 58M 34M 22M 22M 25M 31M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 7137 7131 7112 7109 7109 7109 7154 7268 7302
retainedEarnings -69M -70M -72M -39M -111M -111M -72M -64M -60M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 -0 0 0 0 0 0
othertotalStockholdersEquity 238M 238M 237M 236M 235M 235M 234M 234M 233M
totalStockholdersEquity 169M 168M 165M 197M 124M 124M 162M 170M 173M
totalEquity 169M 168M 165M 197M 124M 124M 162M 170M 173M
totalLiabilitiesAndStockholdersEquity 195M 193M 243M 255M 158M 147M 184M 195M 204M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 195M 193M 243M 255M 158M 147M 184M 195M 204M
totalInvestments 0 0 0 0 0 0 0 0 0
totalDebt 535 234 2M 1M 1M 554 732 545 558 536 627 528 170 519 198
netDebt -99M -105M -143M -149M -71M -76M -115M -98M -109M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol SIGA SIGA SIGA SIGA SIGA SIGA SIGA SIGA SIGA
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-11-07 2024-08-01 2024-05-07 2024-03-12 2023-11-07 2023-08-08 2023-05-04 2023-03-02 2022-11-03
acceptedDate 2024-11-07 16:55:58 2024-08-01 16:59:05 2024-05-07 16:58:12 2024-03-12 17:00:41 2023-11-07 17:00:18 2023-08-08 16:50:42 2023-05-04 16:52:58 2023-03-02 16:55:27 2022-11-03 17:06:16
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome 1M 2M 10M 72M -393 066 -3M -918 255 -811 794 33M
depreciationAndAmortization 128 382 140 839 138 471 137 591 135 924 133 657 131 121 131 203 130 203
deferredIncomeTax 0 -600 257 36 450 -3M -305 833 -857 933 -483 425 -3M 0
stockBasedCompensation 813 774 932 287 1M 462 469 459 823 721 440 408 730 686 417 328 685
changeInWorkingCapital 7M 10M -18M 9M -5M -736 959 25M -4M -38M
accountsReceivables -3M 9M 3M -13M -2M 6M 33M 10M -35M
inventory -9M 8M 2M 715 594 -14M -8M -3M -8M -15M
accountsPayables 766 720 -957 798 -3M 3M 1M 1M -3M 1M -668 540
otherWorkingCapital 18M -5M -19M 19M 10M 335 106 -2M -7M 13M
otherNonCashItems -17M -21M 359 747 16 298 44 390 35 126 483 425 -584 181 10 706
netCashProvidedByOperatingActivities -7M 6M -6M 79M -5M -4M 24M -8M -5M
investmentsInPropertyPlantAndEquipment -22 427 -2185 0 21 686 0 -21 686 0 0 0
acquisitionsNet 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 -2185 0 0 0 0 0 0 0
netCashUsedForInvestingActivites -22 427 -2185 0 21 686 0 -21 686 0 0 0
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 0 0 417 000 0 0 0 0 0 0
commonStockRepurchased 355 539 -196 559 -158 980 11M 0 -4M -8M -3M 0
dividendsPaid 8468 -43M 0 -32M 0 -32M 0 -3919 0
otherFinancingActivites -282 600 -196 559 -158 980 64M 0 -214 794 0 7838 0
netCashUsedProvidedByFinancingActivities -274 132 -43M -158 980 43M 0 -36M -8M -3M 0
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0
netChangeInCash -8M -37M -6M 79M -5M -39M 17M -11M -5M
cashAtEndOfPeriod 99M 107M 144M 150M 71M 76M 116M 99M 110M
cashAtBeginningOfPeriod 107M 144M 150M 71M 76M 116M 99M 110M 115M
operatingCashFlow -7M 6M -6M 79M -5M -4M 24M -8M -5M
capitalExpenditure -22 427 -2185 0 21 686 0 -21 686 0 0 0
freeCashFlow -7M 6M -6M 79M -5M -4M 24M -8M -5M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-07 ET (fiscal 2024 q3)
2024 q2
2024-08-01 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-03-13 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-03-02 ET (fiscal 2022 q4)
2022 q3
2022-11-05 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-05-08 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-10-31 11:30 ET
SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results
2024-10-22 11:30 ET
SIGA Enters into Exclusive License Agreement with Vanderbilt University for Novel Poxvirus Monoclonal Antibodies
2024-10-08 11:30 ET
SIGA Announces Agreement to Supply TPOXX® in Morocco
2024-08-21 20:00 ET
SIGA Announces New Contract Awarded by U.S. Department of Defense for the Procurement of $9 Million of TPOXX®
2024-08-15 11:35 ET
Topline Results from PALM 007 Study of SIGA’s Tecovirimat in Treatment of Mpox Released
2024-08-01 20:05 ET
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2024
2024-07-25 11:30 ET
SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results
2024-07-19 12:00 ET
SIGA Announces U.S. Government Procurement Order of $113 Million for Oral TPOXX®
2024-06-17 20:05 ET
SIGA Announces Agreement to Sell TPOXX® to ASEAN Member States
2024-06-10 11:00 ET
Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors
2024-05-07 20:05 ET
SIGA Reports Financial Results for Three Months Ended March 31, 2024
2024-05-01 21:00 ET
SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results
2024-04-01 20:05 ET
SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX®
2024-03-25 11:30 ET
SIGA Names Larry Miller General Counsel
2024-03-12 20:05 ET
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023
2024-03-12 11:30 ET
SIGA Declares Special Cash Dividend of $0.60 Per Share
2024-03-12 11:30 ET
SIGA Declares Special Cash Dividend of $0.60 Per Share
2024-03-05 12:30 ET
SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results
2024-01-22 12:30 ET
SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer
2023-11-07 21:05 ET
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023
2023-10-26 11:30 ET
SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results
2023-10-23 12:00 ET
SIGA Announces Creation of Joint Procurement Mechanism by European Commission with Anticipated Initial Orders of Approximately $18 Million for Oral TPOXX® (Tecovirimat) by Participating Countries
2023-10-23 12:00 ET
Meridian Medical Technologies, LLC, and the European Commission’s DG HERA Sign Agreement for 13 Countries From the EEA to Purchase Tecovirimat SIGA
2023-09-06 11:30 ET
SIGA Technologies Names Dr. Jay K. Varma as EVP and Chief Medical Officer
2023-08-08 20:05 ET
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2023
2023-07-27 20:45 ET
SIGA Announces U.S. Government Procurement Orders of Approximately $138 Million for Oral and IV TPOXX®
2023-07-27 11:30 ET
SIGA Technologies to Host Business Update Call on Tuesday, August 8th, 2023 Following Release of Second Quarter 2023 Financial Results
2023-06-27 20:05 ET
SIGA CEO Phil Gomez, PhD, to Present on Smallpox and Orthopox Preparedness at NATO Chemical, Biological, Radiological & Nuclear Medical Symposium
2023-05-04 20:05 ET
SIGA Reports Financial Results for Three Months Ended March 31, 2023
2023-05-04 11:30 ET
SIGA Declares Special Cash Dividend of $0.45 Per Share
2023-04-27 11:30 ET
SIGA Technologies to Host Business Update Call on May 4th, 2023 Following Release of First Quarter 2023 Financial Results
2023-03-02 21:05 ET
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2022
2023-02-23 12:30 ET
SIGA Technologies to Host Business Update Call on March 2nd, 2023 Following Release of Fourth Quarter and Full Year 2022 Financial Results
2023-01-17 12:30 ET
SIGA Technologies Announces Planned Retirement of CEO Phil Gomez in 2023
2022-11-03 20:05 ET
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2022
2022-10-27 20:15 ET
SIGA Technologies to Host Business Update Call on November 3rd, 2022 Following Release of Third Quarter 2022 Financial Results
2022-10-12 20:05 ET
SIGA Provides Update on Progress in Clinical Trials to Assess Use of TPOXX ® (tecovirimat) for Treatment of Monkeypox
2022-09-29 11:30 ET
SIGA Technologies Announces New Contract Awarded by U.S. Department of Defense for the Procurement of up to $10.7 Million of Oral TPOXX®
2022-09-26 14:07 ET
SIGA Announces Approximately $16 Million of International Procurement Orders Received in August and Early September for Oral TPOXX® (Tecovirimat)
2022-08-09 11:30 ET
SIGA Announces BARDA Exercise of Procurement Options Valued at Approximately $26 Million for IV TPOXX®
2022-08-04 20:05 ET
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2022
2022-07-28 20:15 ET
SIGA Technologies to Host Business Update Call on August 4th, 2022 Following Release of Second Quarter 2022 Financial Results
2022-07-15 11:30 ET
SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics
2022-07-12 20:15 ET
SIGA Announces Approximately $28 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
2022-07-08 11:30 ET
SIGA Technologies Receives Approval from UK for Tecovirimat
2022-06-23 12:00 ET
SIGA Announces $13 Million of International Procurement Orders for Oral TPOXX® (Tecovirimat)
2022-06-22 14:13 ET
SIGA to Participate in Alliance Global Partners’ Monkeypox Panel on Thursday, June 23rd 2022
2022-05-19 11:30 ET
SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX® (tecovirimat)
2022-05-12 20:05 ET
New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX®
2022-05-05 20:05 ET
SIGA Reports Financial Results for Three Months Ended March 31, 2022
2022-05-05 11:30 ET
SIGA Declares Special Dividend of $0.45 Per Share
2022-04-28 20:05 ET
SIGA Technologies to Host Business Update Call on May 5th, 2022 Following Release of First Quarter 2022 Financial Results
2022-03-03 21:05 ET
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2021
2022-03-02 12:30 ET
SIGA Announces Start of TPOXX® Post-Exposure Prophylactic (“PEP”) Clinical Trials
2022-02-24 15:27 ET
SIGA Technologies to Host Business Update Call on March 3rd, 2022 Following Release of Fourth Quarter and Full Year 2021 Financial Results
2022-01-25 12:30 ET
SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech
2022-01-18 12:30 ET
SIGA Technologies to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
2022-01-10 12:30 ET
SIGA Technologies Receives Approval from the European Medicines Agency for Tecovirimat
2021-12-01 14:55 ET
SIGA Announces Health Canada Regulatory Approval of Oral TPOXX®
2021-11-16 13:30 ET
European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) Recommends Approval of Tecovirimat
2021-11-04 20:05 ET
SIGA Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2021
2021-10-28 20:15 ET
SIGA Technologies to Host Business Update Call on November 4th, 2021, Following Release of Third Quarter 2021 Financial Results
2021-09-13 11:30 ET
SIGA Announces BARDA Exercise of Procurement Option Valued at $112.5 Million for Oral TPOXX®
2021-09-07 17:16 ET
SIGA Technologies CEO to Speak at NCT USA Conference September 8, 2021
2021-08-05 20:15 ET
SIGA Reports Financial Results for Three and Six Months Ended June 30, 2021
2021-07-29 20:15 ET
SIGA Technologies to Host Business Update Call on August 5th, 2021 Following Release of Second Quarter 2021 Financial Results
2021-07-29 07:30 ET
SIGA Announces Collaboration with Oxford University to Support Expanded Access Protocol for Use of TPOXX® (Tecovirimat) To Treat Monkeypox in Central African Republic
2021-06-30 11:30 ET
SIGA Supplies TPOXX® (Tecovirimat) as Compassionate Treatment for Monkeypox Case in the United Kingdom
2021-05-06 20:05 ET
SIGA Reports Financial Results for Three Months Ended March 31, 2021
2021-05-04 11:30 ET
SIGA Announces New Drug Application Filing with FDA for Intravenous Formulation of TPOXX
2021-04-29 12:00 ET
SIGA Technologies to Host Business Update Call on May 6th, 2021 Following Release of First Quarter 2021 Financial Results
2021-03-23 14:30 ET
Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats
2021-03-23 12:00 ET
Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats
2021-03-04 21:05 ET
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2020
2021-02-26 12:30 ET
SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results
2021-01-13 21:45 ET
SIGA Announces Public Health Agency of Canada Contract Award to Purchase Up To Approximately $33 Million of Oral TPOXX®
2020-11-12 21:05 ET
SIGA Technologies Chief Scientific Officer to Participate at NCT Asia Virtual Conference on November 13, 2020
2020-11-05 21:05 ET
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2020
2020-10-29 11:30 ET
SIGA Technologies to Host Business Update Call on November 5, 2020 Following Release of Third Quarter Financial Results
2020-10-08 11:30 ET
SIGA Announces Public Health Agency of Canada Intent to Purchase Up To 33,300 Courses of Oral TPOXX®
2020-09-10 12:30 ET
SIGA to Participate at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020
2020-08-31 11:30 ET
Dr. Dennis Hruby Wins 2021 ASM Award for Applied and Biotechnological Research
2020-08-06 20:05 ET
SIGA Technologies, Inc. Reports Financial Results for Three and Six Months Ended June 30, 2020
2020-07-30 20:01 ET
SIGA Technologies to Host Business Update Call on August 6, 2020 Following Release of Second Quarter Financial Results
2020-07-30 11:30 ET
SIGA Announces Marketing Authorization Filing for oral tecovirimat with the European Medicines Agency for Multiple Indications
2020-06-25 20:05 ET
SIGA Announces Deliveries of Oral TPOXX® to HHS Valued at Approximately $32 Million
2020-06-15 11:30 ET
SIGA Technologies Announces Department of Defense Increases Funding to Develop Post-Exposure Prophylactic Indication for TPOXX® 
2020-06-01 21:00 ET
SIGA Changes its 2020 Annual Meeting of Stockholders to Virtual Format
2020-06-01 13:01 ET
SIGA Technologies Announces First International Delivery of Oral TPOXX®
2020-05-06 20:05 ET
SIGA Technologies, Inc. Reports Financial Results for the First Quarter of 2020
2020-04-29 20:30 ET
SIGA Announces BARDA Exercise of Contract Options Valued at $101.3 Million for the Procurement of Oral TPOXX®
2020-04-29 11:30 ET
SIGA Technologies to Host Business Update Call on May 6, 2020 after Release of First Quarter Financial Results
2020-04-03 14:15 ET
SIGA Announces Award of First International Contract for Oral TPOXX® with Purchase by the Canadian Department of National Defence
2020-03-05 21:05 ET
SIGA Technologies, Inc. Reports Financial Results for  Fiscal Year 2019
2020-03-02 21:30 ET
SIGA Announces Collaboration with Turnstone Biologics
2020-02-20 21:59 ET
SIGA to Host Business Update Call on March 5, 2020 after Release of Year End Financial Results
2019-12-05 17:10 ET
SIGA Announces Canadian Department of National Defence Intent to Purchase Up To 15,325 Courses of Oral TPOXX®
2019-11-18 12:30 ET
SIGA Announces Canadian Release of the Advanced Contract Award Notice to Support Regulatory Filing for Oral TPOXX®
2019-10-21 11:30 ET
SIGA Technologies CEO to Speak at NCT Asia Conference on October 23, 2019
2019-10-03 11:30 ET
SIGA Completes Clinical Studies for IV Formulation of TPOXX®, NDA to be Submitted in 2020   
2019-09-26 11:30 ET
SIGA to Present at the Cantor Fitzgerald Global Healthcare Conference on October 3, 2019
2019-09-25 11:30 ET
SIGA Technologies CSO to Speak at The 13th CBRNe Protection Symposium on September 25, 2019

SEC forms

Show financial reports only

SEC form 10
2025-03-11 17:07 ET
SIGA Technologies reported for 2024 q4
SEC form 8
2025-03-11 16:05 ET
SIGA Technologies reported for 2024 q4
SEC form 8
2025-03-11 16:05 ET
SIGA Technologies published news for 2024 q4
SEC form 10
2025-03-11 00:00 ET
SIGA Technologies reported for 2024 q4
SEC form 10
2024-11-07 16:55 ET
SIGA Technologies reported for 2024 q3
SEC form 8
2024-11-07 16:05 ET
SIGA Technologies published news for 2024 q3
SEC form 8
2024-11-07 16:05 ET
SIGA Technologies reported for 2024 q3
SEC form 10
2024-08-01 16:59 ET
SIGA Technologies reported for 2024 q2
SEC form 8
2024-08-01 16:06 ET
SIGA Technologies reported for 2024 q2
SEC form 8
2024-08-01 16:06 ET
SIGA Technologies published news for 2024 q2
SEC form 10
2024-08-01 00:00 ET
SIGA Technologies reported for 2024 q2
SEC form 10
2024-05-07 16:58 ET
SIGA Technologies reported for 2024 q1
SEC form 8
2024-05-07 16:06 ET
SIGA Technologies published news for 2024 q1
SEC form 8
2024-05-07 16:06 ET
SIGA Technologies reported for 2024 q1
SEC form 10
2024-05-07 00:00 ET
SIGA Technologies reported for 2024 q1
SEC form 10
2024-03-12 17:00 ET
SIGA Technologies reported for 2023 q4
SEC form 8
2024-03-12 16:05 ET
SIGA Technologies reported for 2023 q4
SEC form 8
2024-03-12 16:05 ET
SIGA Technologies published news for 2023 q4
SEC form 10
2024-03-12 00:00 ET
SIGA Technologies reported for 2023 q4
SEC form 10
2023-11-07 17:00 ET
SIGA Technologies reported for 2023 q3
SEC form 8
2023-11-07 16:05 ET
SIGA Technologies published news for 2023 q3
SEC form 10
2023-11-07 00:00 ET
SIGA Technologies reported for 2023 q3
SEC form 10
2023-08-08 16:50 ET
SIGA Technologies reported for 2023 q2
SEC form 6
2023-08-08 16:05 ET
SIGA Technologies reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
SIGA Technologies reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
SIGA Technologies reported for 2023 q2
SEC form 6
2023-07-28 16:08 ET
SIGA Technologies published news for 2023 q2
SEC form 6
2023-07-28 07:08 ET
SIGA Technologies published news for 2023 q2
SEC form 6
2023-06-15 17:07 ET
SIGA Technologies published news for 2023 q1
SEC form 6
2023-06-15 16:01 ET
SIGA Technologies published news for 2023 q1
SEC form 10
2023-05-04 00:00 ET
SIGA Technologies reported for 2023 q1
SEC form 8
2023-05-04 00:00 ET
SIGA Technologies reported for 2023 q1
SEC form 10
2023-03-02 16:55 ET
SIGA Technologies reported for 2022 q4
SEC form 6
2023-03-02 16:32 ET
SIGA Technologies reported for 2022 q4
SEC form 10
2023-03-02 00:00 ET
SIGA Technologies reported for 2022 q4
SEC form 8
2023-03-02 00:00 ET
SIGA Technologies reported for 2022 q4
SEC form 6
2023-01-17 16:37 ET
SIGA Technologies published news for 2022 q4
SEC form 6
2022-11-14 17:27 ET
SIGA Technologies published news for 2022 q3
SEC form 10
2022-11-03 17:06 ET
SIGA Technologies reported for 2022 q3
SEC form 6
2022-11-03 16:05 ET
SIGA Technologies reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
SIGA Technologies reported for 2022 q3
SEC form 8
2022-11-03 00:00 ET
SIGA Technologies reported for 2022 q3
SEC form 6
2022-08-09 07:46 ET
SIGA Technologies published news for 2022 q2
SEC form 10
2022-08-04 17:16 ET
SIGA Technologies reported for 2022 q2
SEC form 6
2022-08-04 16:16 ET
SIGA Technologies published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
SIGA Technologies reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
SIGA Technologies reported for 2022 q2
SEC form 6
2022-07-12 16:15 ET
SIGA Technologies published news for 2022 q2
SEC form 6
2022-06-16 16:15 ET
SIGA Technologies published news for 2022 q1
SEC form 10
2022-05-05 16:55 ET
SIGA Technologies reported for 2022 q1
SEC form 6
2022-05-05 16:15 ET
SIGA Technologies published news for 2022 q1
SEC form 6
2022-05-05 07:34 ET
SIGA Technologies published news for 2022 q1
SEC form 10
2022-05-05 00:00 ET
SIGA Technologies reported for 2022 q1
SEC form 8
2022-05-05 00:00 ET
SIGA Technologies reported for 2022 q1
SEC form 6
2022-04-27 17:00 ET
SIGA Technologies published news for 2022 q1
SEC form 6
2022-04-13 17:10 ET
SIGA Technologies published news for 2022 q1
SEC form 6
2022-03-24 17:11 ET
SIGA Technologies published news for 2021 q4
SEC form 10
2022-03-03 17:15 ET
SIGA Technologies published news for 2021 q4
SEC form 6
2022-03-03 16:25 ET
SIGA Technologies published news for 2021 q4
SEC form 8
2022-03-03 00:00 ET
SIGA Technologies published news for 2021 q4
SEC form 10
2022-03-03 00:00 ET
SIGA Technologies published news for 2021 q4
SEC form 6
2021-12-15 16:58 ET
SIGA Technologies published news for 2021 q3
SEC form 10
2021-11-04 16:59 ET
SIGA Technologies published news for 2021 q3
SEC form 6
2021-11-04 16:16 ET
SIGA Technologies published news for 2021 q3
SEC form 10
2021-11-04 00:00 ET
SIGA Technologies published news for 2021 q3
SEC form 8
2021-11-04 00:00 ET
SIGA Technologies published news for 2021 q3
SEC form 6
2021-09-15 17:28 ET
SIGA Technologies published news for 2021 q2
SEC form 6
2021-09-09 17:11 ET
SIGA Technologies published news for 2021 q2
SEC form 10
2021-08-05 17:03 ET
SIGA Technologies published news for 2021 q2
SEC form 6
2021-08-05 16:24 ET
SIGA Technologies published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
SIGA Technologies published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
SIGA Technologies published news for 2021 q2
SEC form 6
2021-06-17 16:16 ET
SIGA Technologies published news for 2021 q1
SEC form 10
2021-05-06 17:05 ET
SIGA Technologies published news for 2021 q1
SEC form 6
2021-05-06 16:05 ET
SIGA Technologies published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
SIGA Technologies published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
SIGA Technologies published news for 2021 q1
SEC form 6
2021-04-27 17:01 ET
SIGA Technologies published news for 2021 q1
SEC form 10
2021-03-04 17:09 ET
SIGA Technologies published news for 2020 q4
SEC form 6
2021-03-04 16:20 ET
SIGA Technologies published news for 2020 q4
SEC form 6
2021-01-22 17:02 ET
SIGA Technologies published news for 2020 q4
SEC form 6
2021-01-13 17:23 ET
SIGA Technologies published news for 2020 q4
SEC form 6
2020-12-11 16:56 ET
SIGA Technologies published news for 2020 q3
SEC form 10
2020-11-05 17:02 ET
SIGA Technologies published news for 2020 q3
SEC form 6
2020-11-05 16:21 ET
SIGA Technologies published news for 2020 q3
SEC form 6
2020-10-02 16:39 ET
SIGA Technologies published news for 2020 q3